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ORIGINAL RESEARCH
Abstract: Chronic lipopolysaccharide (LPS) exposure may contribute to the pathogenesis of a 
number of lung diseases including COPD and emphysema. We sought to develop a large- animal 
model of emphysema using repeated LPS administration into sheep lung segments. An experi-
mental protocol was designed to facilitate comparisons with elastase-treated and control segments 
within the same lung of individual sheep. Histopathologic evaluation of segments treated with 
LPS demonstrated low-grade inﬂ  ammation characterized by an increase in the number of intra-
alveolar macrophages and lymphocytes. Treated segments demonstrated a signiﬁ  cant reduction 
in airspace surface area (ASA), an increase in percent disrupted alveolar attachments and the 
distance between normal alveolar attachments, and a reduction in the number of normal alveolar 
attachments surrounding nonrespiratory bronchioles. Coefﬁ  cient of variation of individual ASA 
measurements in elastase-treated segments was indicative of a heterogeneous parenchymal 
response, in contrast to that associated with chronic LPS treatment. Our results demonstrate that 
chronic LPS treatment of individual lung segments in sheep induces microscopic emphysema 
qualitatively and quantitatively consistent with both accepted pathologic deﬁ  nitions of this 
condition and with that produced by airway instillation of elastolytic enzymes. Development 
of this phenotype is associated with evidence of downregulated activation of transforming 
growth factor beta.
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Introduction
Emphysema is mostly associated with smoking (Janoff 1983) and is also seen in 
individuals with a severe genetic deﬁ  ciency in serum levels of a-1 antiprotease (Laurell 
and Ericksson 1963). The pathology, featuring permanent enlargement of airspaces 
distal to the terminal bronchiole, is linked to the destruction of alveolar walls (Snider 
et al 1986) in a process characterized by degradation and fraying of the elastic ﬁ  bre 
network (Fukuda et al 1989; Wright 1961). These features together with the initial 
observation of Gross et al (1964) that intratracheal administration of papain to rats 
caused similar pathology, led to the concept that emphysema might be mediated at 
least in part through proteolytic damage.
This hypothesis is largely accepted and serine proteases and metalloproteases 
from neutrophils and macrophages respectively are thought to be the major source 
of elastolytic activity (Shapiro 1994; Finlay et al 1997; Pardo and Selman 1999) in 
emphysema. Cigarette smoking leads to the recruitment of these inﬂ  ammatory cells and 
also damages the antiprotease screen as a consequence of free radical production.
Emphysema has been extensively modeled in animals (Snider et al 1986), most 
models relying upon the direct intratracheal instillation or inhalation of proteolytic 
enzymes. The early tissue damage arising as a consequence is characterized by edema, 
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hemorrhage, and a modest inﬁ  ltration of neutrophils and 
macrophages (Snider et al 1986). Thereafter there is evidence 
of tissue repair involving synthesis of new elastin (Mercer 
and Crapo 1992).
A common and justiﬁ  ed criticism of such models is that 
the acute nature of disease induction fails to represent the 
slow progression of the disease in man. As Snider et al (1986) 
point out “The artiﬁ  ciality of putting a large quantity of an 
elastolytic enzyme into the lungs of an animal severely limits 
the usefulness of this model in answering questions relating 
to mechanisms of human emphysema.”
This concern has led to a number of groups developing 
small-animal models in which inﬂ  ammatory cell recruitment 
with presumed release of endogenous proteinase is induced 
by repeated instillation of lipopolysaccharide (LPS) and leads 
to the development of emphysematous lesions (Stolk et al 
1992; Rudolphus et al 1993; Lawson et al 1995; Vernooy 
et al 2002).
It was our contention that such a strategy could equally 
be applied within the context of a large-animal model sys-
tem. The major advantage of using such a system, namely 
the ability to differentially and repeatedly treat different 
areas within the same lung, allows for the direct and 
meaningful comparison of different treatment protocols. 
Such an approach has obvious advantages with respect to 
being able to treat each animal as its own control, thereby 
counteracting inter-animal variation and reducing the 
group sizes required to adequately test hypotheses. Fur-
ther, treatments administered at the segmental level are 
potentially less likely to clinically affect the animal, hold 
clear relevance for future evaluation of therapeutic strate-
gies delivered directly to the lung, and hold potential for 
translation into therapeutic protocols directed at human 
subjects. Our experience (Collie et al 1999, 2001), together 
with that of others (Begin et al 1981), that sheep tolerate 
repeated anesthesia and bronchoscopic intervention par-
ticularly well, further complemented our approach.
We determined to assess the response of the sheep lung 
to repeated endobronchial administration of LPS. Our 
hypothesis was that such a strategy would engender a state 
of chronic inﬂ  ammation and that this inﬂ  ammation would 
persistently imbalance the relative inﬂ  uence of proteases 
and antiproteases in the lung, leading to the development 
of pulmonary emphysema. We sought to compare this 
model with the established principle of producing emphy-
sema through local lung administration of elastase. Further, 
recognizing the potential role for pulmonary remodeling 
involving collagen and elastin synthesis in emphysema 
(Vlahovic et al 1999), we sought to deﬁ  ne the pattern of 
regulation of the pro-ﬁ  brotic cytokine, transforming growth 
factor beta (TGF-β) in this model.
Our results demonstrate that chronic LPS treatment of 
individual lung segments in sheep induces microscopic 
emphysema qualitatively and quantitatively consistent with 
accepted pathologic deﬁ  nitions of this condition, and that the 
development of this phenotype is associated with evidence 
of mild mononuclear alveolitis and downregulated activation 
of TGF-β. Our results also demonstrate changes common to 
all lung segments, regardless of treatment schedule. These 
changes consist of a progressive low-grade neutrophilic 
inﬂ  ammation coupled with evidence of a reduction in the 
elastase inhibitory capacity present in the bronchoalveolar 
space.
Materials and Methods
Animals
Eight adult crossbred sheep (Suffolk cross; 5 F and 3 MN) 
(bodyweight: 48–57 kg) were used in this study. Animals 
were judged to be free from signiﬁ  cant pulmonary disease 
on the basis of clinical examination by a veterinary surgeon, 
a subjective opinion subsequently conﬁ  rmed at necropsy. 
All experimental procedures were subject to ethical review 
and were performed under license, as required by the United 
Kingdom’s Animals (Scientiﬁ  c Procedures) Act 1986.
Materials
Four hundred units of puriﬁ  ed porcine elastase (PPE) were 
prepared in 20 mL saline (200 units/mL) for each segmental 
instillation. LPS was derived from Mannheimia haemolytica 
by phenol extraction. Three millilitres of a sterile, 150 μg/mL 
suspension of M. haemolytica LPS in saline (SAL) were 
prepared for each segmental instillation. A volume of 3 mL 
SAL was prepared for each segmental instillation.
Experimental design
Four spatially disparate lung segments were selected on 
bronchoscopic examination and their position carefully 
mapped. The segments were randomly assigned to one 
of four treatment protocols. A sample of bronchoalveolar 
lavage ﬂ  uid (BALF) was collected from each segment for 
cytological examination. Treatment protocols consisted 
of an initial instillation of either SAL (segment A), LPS 
(segment B), or PPE (segments C and D) followed, at 4- to 
7-day intervals by 7 instillations of either SAL (segments 
A and C) or LPS (segments B and D). Additional BALF International Journal of COPD 2006:1(2) 191
Modeling emphysema in sheep
was collected after 3 instillations (day 14) and 1 week 
after the 8th instillation (day 39). Sheep were killed on 
day 39 and submitted for post-mortem examination and 
collection of tissues for morphometric evaluation. The 
treatment protocol is outlined in Table 1.
Anesthesia and ventilation
Food was withheld for 12 hours prior to anesthesia which 
was achieved by intravenous administration of a single bo-
lus of thiopentone sodium (Intraval sodium; Merial Animal 
health Ltd, Harlow, Essex, UK) at a dose rate of 20 mg/kg 
bodyweight. Thereafter sheep were intubated and anesthesia 
maintained using gaseous halothane (2%–3%) in oxygen 
and nitrous oxide. The sheep were placed in sternal recum-
bency in a large plexiglass whole-body respirator (internal 
volume 388 L). The proximal end of the endotracheal tube 
was connected to the anesthetic circuit through a connector 
in the wall of the box. Pressure in the box was varied by 
appropriate connection to a large bellows pump (Cuirass; 
Cape Warwick, Warwick, UK) which induced a sinusoidal 
tidal respiratory pattern, the rate and magnitude of which 
could be controlled by adjustment of the pump itself. The 
magnitude of pressure ﬂ  uctuations were adjusted to maintain 
a tidal volume of 10 mL/kg bodyweight. Respiratory rate 
was adjusted to maintain end-tidal CO2 measurements in the 
range 4.5%–5.5% (Oxicap Monitor Model 4700; Ohmeda, 
Louisville, CO, USA).
Bronchoalveolar lavage
A ﬂ  exible ﬁ  bre optic bronchoscope (5.3  mm OD) (Model 
FG-16X; Pentax UK Ltd, Slough, UK) was advanced and 
wedged in selected segmental bronchi. The subtended 
segments were lavaged by installation and withdrawal of 
2 20-mL aliquots of normal saline (0.9% NaCl solution). 
BALF was immediately placed on ice until subsequent 
analysis.
Sample handling
Lavage fluid from each lung lobe was separated into 
supernatant and cells by centrifugation at 400 g for 7 minutes 
and the resultant cell pellets were resuspended in phosphate 
buffered saline (PBS) before differential cytology was 
determined. Supernatants were recentrifuged at 1000 g at 
4°C for 20 minutes. The samples were stored at –70oC until 
analysis of TGF-β1, elastase, and inhibitor levels.
Differential cytology
Cells were counted using a Neubauer hemocytometer and 
values expressed per millilitre BALF. Cytocentrifuge slides 
were prepared and stained using Leishmann’s stain for dif-
ferential counts on 400 cells. Cells were classiﬁ  ed as neu-
trophils, macrophages, eosinophils, lymphocytes, or mast 
cells according to standard morphological criteria. Cells 
not classiﬁ  ed in the aforementioned groups were recorded 
as “other” cells.
Neutrophil elastase and neutrophil 
elastase inhibitor assays
BALF samples were concentrated 10× by freeze drying 
and re-dissolving in a 1/10 volume of sterile water. A stock 
concentration of 10 mg/mL neutrophil elastase substrate 
(N-methoxysuccinyl-Ala-Ala-Pro-Val p-Nitroanalide 
[Sigma] in DMSO [Sigma]) was prepared and stored at 
4°C. A 50 μl volume of this stock was diluted to 0.1 mg/mL 
in 50 mM Tris; 0.5 M NaCl, 0.1% Triton X-100, pH 8.0. 
Standards of human sputum elastase (HSE, Elastin Products 
Company, Owensville MO, USA) ranging from 250 μg/50mL 
to 10 ng/50 μL were prepared in 50 mM sodium acetate, 
0.5M NaCl, pH 4.5. To a 96-well microtitre plate, 50 ml of 
concentrated BALF or HSE standard solution was incubated 
with 50 μl of substrate. After equilibration for 1 minute the 
absorbance was measured at 405 nm in a Dynatech MRX 
plate reader at 37°C for each sample at 1-minute intervals for 
15 minutes. The optimal elastase activity reading of the BALF 
Table I Experimental protocol. Four segments (A–D) were 
randomly assigned to treatment protocols. Bronchoalveolar 
lavage (BAL) was employed to collect ﬂ  uid from segments A–D 
for cytological examination prior to (day –7), during (day 14), 
and at the completion (day 39) of the study. Treatment pro-
tocols consisted of an initial instillation of either saline (SAL) 
(segment A), lipopolysaccharide (LPS) (segment B), or puriﬁ  ed 
porcine elastase (PPE) (segments C and D) followed at 4- to 7-
day intervals by 7 instillations of either SAL (segments A and C) 
or LPS (segments B and D). Animals were killed on day 39 and 
submitted for post-mortem examination (PME) and collection of 
tissues for morphometric assessment.
   Segment   
Day A  B  C  D
–7 BAL  BAL  BAL  BAL
0 SAL  LPS  PPE  PPE
4 SAL    LPS  SAL  LPS
8 SAL  LPS  SAL  LPS
14 BAL  BAL  BAL  BAL
14–32 SALx5a  LPSx5a  SALx5a  LPSx5a
39 BAL/PME BAL/PME  BAL/PME BAL/PME
a administered at 4- to 7-day intervals.International journal of COPD 2006:1(2)
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was taken to be the time point at which the readings ceased to 
be linear. Absorbances were compared with control samples 
and the levels of elastase in the samples estimated.
Elastase inhibitor activity assay
HSE stock was diluted to 100 ng/10 μl in 50 mM sodium 
acetate, 0.5 M NaCl, pH 4.5. BAL was serially diluted down 
to 1/572 in 50 mM Tris, 0.5M NaCl, 0.1% Triton X-100, pH 
8.0. To each well of a 96-well microtitre plate, 10 ml of BAL 
dilution was incubated with 30 μl 50 mM 0.5 M NaCl, 0.1% 
Triton X-100, pH 8.0 and 10 ml HSE. Following incubation 
at 37°C, 5% CO2 for 15 minutes, 50 μl of substrate was added 
and equilibrated for 1 minute. The absorbance was read at 
405 nm at 1-minute intervals for 15 minutes. The level of 
inhibition (decrease in absorbance at 405 nm) of the HSE 
was directly proportional to the amount of elastase inhibitors 
present in the BAL.
Measurement of TGF-β in BALF
TGF-β levels in BALF supernatant were measured using 
minor modiﬁ  cations of the procedure described by Abe 
et al (1994). Brieﬂ  y, BALF supernatant was ﬁ  ltered through 
2 layers of sterile muslin and pre-spun in Vectaspin micro 
anopore ﬁ  lters (Whatman International Ltd., Maidstone, Kent, 
UK) at 13 000 rpm for 5 minutes to remove cell debris. The 
supernatant was then concentrated 5 × by means of Vivaspin 
0.5 mL concentrators (Vivascience Ltd, Gloucestershire, UK; 
10 000 MW cut-off) used according to the manufacturer’s 
instructions.
Because TGF-β is secreted in a latent form acid activation 
is required to release active TGF-β from the latent complex. 
Relevant aliquots were acid-activated by the addition of 
5M HCl. Thereafter the samples were neutralized and sub-
mitted for assay.
Mink lung epithelial cells (MLEC) stably transfected 
with an expression construct containing a truncated plas-
minogen activator inhibitor-1 (PAI-1) promoter fused to 
the ﬁ  reﬂ  y luciferase gene were used as the reporter system. 
TGF-β, through its induction of PAI-1 expression, causes 
dose-dependent increases in luciferase activity in this 
system (Abe et al 1994). MLECs were maintained at 37°C 
in Dulbecco’s Modiﬁ  ed Eagles Medium (DMEM), 10% 
fetal bovine serum containing penicillin–streptomycin, 
L-glutamine, and G418 (geneticin 200 mg/ml) (Life Tech-
nologies, Cambridge, UK). The sample assay involved 
removing and replacing cell medium with 100 μl BALF 
supernatant. Assay plates were incubated overnight. 
Thereafter the cells were washed and lysed and the lysate 
added to opaque-walled 96-well plates (Dynex Technolo-
gies, Middlesex, UK). Samples were read in a Reporter™ 
microplate luminometer (Turner Designs Inc., Sunnyvale, 
CA, USA) using a luciferase substrate for a single ﬂ  ash 
reaction. Samples were read against a standard curve pre-
pared using appropriate dilutions of human recombinant 
TGF-β1 (R&D Systems Europe Ltd, Oxon, UK).
Tissue handling
Lung tissue was ﬁ  xed by airway instillation of 4% parafor-
maldehyde (pH 7.0) at an inﬂ  ation pressure of 2.5 to 3.0 kPa 
for 3 days. Following ﬁ  xation, 3 tissue blocks were sampled 
from each lung segment and routinely processed and em-
bedded in parafﬁ  n. Serial 4-μm sections were cut from the 
tissue blocks and stained with hematoxylin and eosin for 
morphometric analysis.
Tissue sections were blinded for the purposes of his-
topathologic and morphometric evaluation.
Morphometric analysis
Twelve sections were available from each animal for 
analysis (3 from each of 4 segments). Fields (0.07 mm2) 
within each section were randomly selected. If the ex-
amined ﬁ  elds satisﬁ  ed deﬁ  ning criteria for parenchyma 
(absence of airways or vessels over 1 mm diameter) mor-
phometric measurements were made. Airspace wall tissue 
was selected using an image analyzer (Quantimet Q500C, 
Leica, Cambridge, UK) and, after interactive editing to 
ﬁ  ll in small vessels and remove debris, total airspace 
wall length per unit area (ASA) was measured as mm per 
mm2. To ensure that a stable running mean was obtained, 
the relative standard error (RSE) of measurements from 
ﬁ  elds, ie, the size of the standard error relative to the 
mean value, was reduced to less than 3%. Heterogeneity 
of ASA measurements within segments was estimated by 
calculating the coefﬁ  cent of variation for measurements 
(this is a unitless quantity indicating the variability around 
the mean in relation to the size of the mean).
The loss of alveolar attachments extending radially 
from the outer wall of nonrespiratory bronchioles less than 
1 mm diameter was also quantiﬁ  ed in a manner similar to 
that described by Saetta et al (1985). Ten airways were se-
lected from each segment and the number of complete and 
abnormal alveolar attachments were counted. Tangentially 
or partially cut bronchioles were excluded from analysis. 
The outer circumference of the bronchiole was interactively International Journal of COPD 2006:1(2) 193
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measured using the image analysis package and the results 
expressed as the average number of normal attachments, the 
distance between normal attachments (distance = external 
circumference/[no. attached]) and the percentage of abnor-
mal attachments (% abnormal = [number of abnormal/(no. 
attached + number of abnormal) × 100).
All morphometric analysis was completed by the same 
operator (NMcL). Reproducibility of ASA measurements 
was assessed by repeated analysis of stored images from 6 
parenchymal ﬁ  elds over 2 weeks. Similarly 15 bronchioles 
were analyzed on a repeated basis for loss of alveolar attach-
ments. The coefﬁ  cient of variation for repeated measurements 
by the same operator was 2% for ASA measurements, and 
7%, 4%, and 7% for the number of alveolar attachments, 
the distance between attachments, and the percentage of 
abnormal attachments, respectively.
Data analysis
Within sheep, between-segment comparisons and within-
segment, over-time comparisons were assessed using a Friedman 
two-way analysis of variance followed by Wilcoxon matched pairs 
signed rank tests where signiﬁ  cant differences were indicated.
Results
Animals tolerated the procedure well. No cumulative effect of 
repeated anesthesia was apparent, nor was there any observed 
clinical evidence of respiratory dysfunction as a result of the 
treatment protocol.
Qualitative and quantitative changes in BALF cellularity 
as a consequence of the experimental protocol were apparent 
in all segments including the SAL:SAL segment. Changes 
were consistent between segments and comprised increased 
absolute numbers of neutrophils, and decreased numbers of 
mast cells and eosinophils over time (Table 2). The magnitude 
of change was also consistent between segments. A nonsig-
niﬁ  cant trend towards increased neutrophils (p = 0.07), and 
no signiﬁ  cant change in eosinophil cell numbers (p = 0.26) 
in the PPE:LPS segments were the exceptions to the above. 
Segment-speciﬁ  c changes in absolute neutrophil cell numbers 
in BALF are depicted in Figure 1. At no time did the median 
percentage of neutrophils rise above 3% in any one segment 
(data not shown).
Compared with recoveries on day –7, signiﬁ  cantly less 
BALF was recovered on day 39 in PPE:LPS segments, and 
on day 14 and day 39 in LPS:LPS segments.
Comparing between segments at speciﬁ  c time points 
highlighted a signiﬁ  cant increase in the numbers of macro-
phages and lymphocytes in BALF from the treated segments 
at day 14 compared with SAL:SAL segments (p < 0.05). The 
number of macrophages in BALF from PPE:SAL segments 
was also signiﬁ  cantly increased at day 39 compared with 
SAL:SAL segments (p < 0.05).
Table 2 Absolute cell counts (cells/mL BALF × 104; median [range]) in bronchoalveolar lavage ﬂ  uid (BALF) obtained prior to (day 
–7), during (day 14), and at the conclusion of (day 39) the treatment protocol. Dynamic changes over time within each segment, and 
differences between segments at speciﬁ  c time points for each variable, were assessed using a Friedman nonparametric analysis of 
variance. Where signiﬁ  cance (p < 0.05) could be demonstrated, further analysis, using Wilcoxon signed rank procedures, compared 
results obtained on day 14 and day 39 with those obtained on day –7, and compared results from treated segments with those from 
SAL:SAL segments at each time point.
Segment  Day  BALF volume  Macrophages  Neutrophils  Lymphocytes  Eosinophils  Mast cells  Other cells
   (mL) 
  –7  22.5 (19–26)  12.61 (4.70–36.50)  0.06 (0.00–0.17)  0.64 (0.13–2.87)  0.06 (0.00–0.22)  0.05 (0.00–0.93)  0.00 (0.00–0.00)
SAL:SAL  14  22.5 (15–27)  9.29 (5.08–13.02)  0.20 (0.00–0.75)  0.67 (0.17–2.19)  0.01 (0.00–0.08)  0.00 (0.00–0.06)a  0.00 (0.00–0.00)
  39  20.0 (10–23)  12.28 (8.73–27.12)  0.43 (0.16–2.86)a  1.23 (0.20–3.66)  0.00 (0.00–0.06)a  0.00 (0.00–0.05)  0.00 (0.00–0.00)
  –7  23.0 (19–25)  15.16 (7.09–26.01)  0.08 (0.02–0.16)  1.49 (0.42–1.94)  0.06 (0.00–0.21)  0.04 (0.00–1.42)  0.00 (0.00–0.00)
PPE:SAL  14  24.5 (22–25)  16.95 (8.69–23.83)b  0.28 (0.02–0.82)a  1.52 (0.97–3.56)b  0.05 (0.00–0.93)  0.00 (0.00–0.08)  0.00 (0.00–0.00)
  39  20.0 (17–24)  20.63 (17.26–24.97)b  0.34 (0.08–3.09)a  0.98 (0.34–9.17)  0.00 (0.00–0.05)a  0.00 (0.00–0.04)a  0.00 (0.00–0.00)
  –7  23.0 (20–28)  20.07 (14.40–50.47)  0.09 (0.00–0.21)  1.47 (0.85–7.33)  0.06 (0.00–2.42)  0.14 (0.00–0.29)  0.00 (0.00–0.00)
PPE:LPS  14  22.0 (17–26)  19.38 (10.41–44.25)b  0.22 (0.00–1.33)  2.90 (1.57–11.29)b  0.04 (0.00–0.32)  0.00 (0.00–0.00)a  0.00 (0.00–0.00)
 39  20.0  (16–22)a  24.29 (7.00–41.96)a  0.27 (0.04–1.11)  2.29 (1.18–2.90)  0.00 (0.00–0.06)  0.01 (0.00–0.15)a  0.00 (0.00–0.00)
  –7  24.5 (21–27)  21.77 (4.70–26.04)  0.04 (0.00–0.11)  1.24 (0.35–2.68)  0.08 (0.00–0.33)  0.05 (0.00–1.53)  0.00 (0.00–0.00)
LPS:LPS 14  22.0  (15–26)a  16.67 (8.77–33.99)b  0.19 (0.00–2.82)a  1.63 (0.93–10.17)b  0.00 (0.00–0.10)  0.00 (0.00–0.00)a  0.00 (0.00–0.00)
 39  19.5  (17–24)a  27.21 (4.77–35.35)  0.38 (0.06–3.18)a  1.06 (0.27–6.09)  0.00 (0.00–0.08)a  0.03 (0.00–0.14)  0.00 (0.00–0.00)
a result signiﬁ  cantly different from that obtained on day –7 (p<0.05); bresult signiﬁ  cantly different from that obtained for the SAL:SAL segment at that time point (p<0.05). International journal of COPD 2006:1(2)
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Figure 1 Boxplot depicting the change in absolute neutrophil counts (cells/mL 
BALF × 104; median [range]) over time with individual symbols shown. Changes over 
time were signiﬁ  cant (p < 0.05) in all bar the PPE:LPS segment (p = 0.07).
Abbreviations Figures 1–8: ASA, airspace surface area; BALF, bronchoalveolar 
ﬂ  uid; LPS, lipopolysaccharides; PPE, puriﬁ  ed porcine elastase; SAL, saline.
Figure 2 Airspace surface area (ASA) measurement values (mm/mm2) in lung 
segments. Each dot represents the mean value calculated on the basis of measure-
ments made on randomly selected ﬁ  elds in sections taken from blocks (n = 3) from 
each segment. Different symbols represent individual sheep. The extremes of the 
box represent the upper and lower quartiles. The median value of the data set is 
represented by a horizontal line within the box. Each “whisker” represents 25% 
of the data and the extremities of these whiskers are the minimum and maximum 
values of the data. The horizontal lines at the top of the graph indicate where 
signiﬁ  cant differences exist between groups (p < 0.05).
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Figure 4 Number of normal alveolar attachments surrounding nonrespiratory 
bronchioles < 1 mm diameter. Each dot represents the mean value calculated on 
the basis of measurements made on 10 airways randomly selected from sections 
taken from 3 blocks from each segment. See Figure 2 legend for explanation of 
boxplots.
Histopathological evaluation of PPE:LPS and LPS:LPS 
segments revealed a low-grade alveolitis characterized by 
increased numbers of intra-alveolar macrophages and lym-
phocytes. Airways were largely unaffected. PPE:SAL and 
SAL:SAL segments were considered histologically normal 
but for incidental changes consistent with sheep managed 
under identical circumstances.
All 3 treatments caused a signiﬁ  cant drop in ASA rela-
tive to SAL:SAL segments (p < 0.05; Figure 2). ASA from 
PPE:SAL- and PPE:LPS-treated segments was signiﬁ  cantly 
lower than ASA from LPS:LPS-treated segments. ASA 
measurements were signiﬁ  cantly more variable, as assessed 
using the coefﬁ  cient of variation (CV), in segments treated 
with PPE compared with measurements obtained from 
SAL:SAL segments (p < 0.05; Figure 3). Although ASA 
measurements from PPE:SAL segments were signiﬁ  cantly 
more variable than those from LPS:LPS segments (p < 0.05), 
comparisons between LPS:LPS and PPE:LPS segments for 
this measurement were nonsigniﬁ  cant (p = 0.093). The CV for 
ASA measurements was 6.7% (4.9–10.7) [median (range)], 
7.5% (3.4–15.2), 12.4% (10.0–20.7), and 10.9% (7.3–17.4) 
for SAL:SAL, LPS:LPS, PPE:SAL, and PPE:LPS segments, 
Figure 3 Coefﬁ  cient of variation of individual ASA measurement values. Each dot 
represents the value calculated on the basis of all individual ASA measurements 
made on each segment from each sheep. See Figure 2 legend for explanation of 
boxplots.
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Figure 7 Plots showing elastase inhibitory activity in BALF obtained from individual lung segments both prior to (day –7) and after (day 39) the different treatment proto-
cols. Different symbols represent individual sheep. Levels of signiﬁ  cance of changes are shown (Wilcoxon signed rank test). The horizontal bars depict mean values.
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Figure 6 The percentage disruption of normal alveolar attachments (distance = ex-
ternal circumference/(no. attached)) and the percentage of abnormal attachments 
(% abnormal = [number of abnormal/(no. attached + number of abnormal)] × 100). 
Each dot represents the mean value calculated on the basis of measurements made 
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ment. See Figure 2 legend for explanation of boxplots.     denotes an outlier.
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respectively. There were signiﬁ  cantly fewer normal alveolar 
attachments in the airways from treated segments relative to 
the SAL:SAL segment (Figure 4). There was a signiﬁ  cantly 
greater distance between normal alveolar attachments in 
the treated segments compared with the SAL:SAL segment 
(Figure 5). The distance between alveolar attachments sur-
rounding airways from PPE:LPS segments was signiﬁ  cantly 
greater than from LPS:LPS segments. Airways from treated 
segments had a signiﬁ  cantly greater percentage of disrupted 
alveolar attachments than airways from SAL:SAL segments 
(Figure 6). Airways from PPE:LPS segments had a signiﬁ  -
cantly greater percentage of disrupted alveolar attachments 
than airways from PPE:SAL segments.
Levels of neutrophil elastase in BALF did not show any 
evidence of signiﬁ  cant change, either within any segment 
Figure 8 Plots showing levels of active transforming growth factor-β1 (TGF-β1) in BALF obtained from individual lung segments both prior to (day –7) and after (day 39) 
the different treatment protocols. Different symbols represent individual sheep. Levels of signiﬁ  cance of changes are shown (Wilcoxon signed rank test). The horizontal 
bars depict mean values.
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over time or between segments within animals (data not 
shown). Elastase inhibitor activity in BALF declined over 
time in all segments, with the decline in activity between day 
–7 and day 39 being signiﬁ  cant for all bar the LPS:LPS seg-
ment in which a nonsigniﬁ  cant trend was apparent (p = 0.093; 
Figure 7). Overall, pooling all the data from individual lung 
segments, the decline in elastase inhibitory activity was sig-
niﬁ  cantly negatively correlated with the absolute number of 
neutrophils in BALF (p = 0.02).
Total TGF-β levels in BALF did not show any evidence 
of signiﬁ  cant change, over time. In contrast, in LPS:LPS 
segments, levels of active TGF-β in BALF decreased signiﬁ  -
cantly (p < 0.05) over time. Similarly the reduction in levels of 
active TGF-β in BALF from PPE:LPS segments approached 
signiﬁ  cance (p = 0.05; Figure 8).International Journal of COPD 2006:1(2) 197
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Discussion
Of the indices studied, a reduction in ASA reﬂ  ects an 
increase in the size of individual airspaces. In humans, 
such measurements are particularly sensitive to detecting 
panacinar emphysema, in which the enlargement of air-
spaces involves the whole acinar unit and the distinction 
between alveoli and alveolar ducts is lost. In contrast, with 
centriacinar emphysema, where sharply demarcated em-
physematous spaces are separated from the acinar periph-
ery by intact normal alveolar ducts and alveolar sacs, there 
may be minimal inﬂ  uence on the overall ASA value. In the 
latter instance early focal changes are often detectable as 
an increased CV of individual measurements (Lamb 1996). 
The signiﬁ  cant decrease in ASA in LPS:LPS, PPE:SAL, 
and PPE:LPS segments relative to SAL:SAL segments 
suggests that either the pattern of disruption is panacinar 
in nature or that the extent of centriacinar disruption is 
sufﬁ  ciently widespread to inﬂ  uence the measurement of 
ASA. The greater CV of ASA measurements in PPE-
treated segments suggests the latter. What is of interest is 
that in the LPS:LPS segments a signiﬁ  cant and uniform 
reduction in ASA occurred, suggesting differences in the 
model phenotype and possibly also in the pathogenesis 
when compared with elastase-treated segments. Such 
ﬁ  ndings are consistent with observations from tissue sec-
tions from lungs of LPS-instilled hamsters, in which the 
emphysematous lesions appeared more diffuse in the lung 
compared with elastase-induced emphysema, in which 
patchy airspace enlargement is mainly located around the 
airways (Snider et al 1984; Stolk et al 1992).
An increase in the interalveolar attachment distance is 
recognized in emphysema (Linhartova et al 1982). Such 
measurement reﬂ  ects the degree of parenchymal support 
to bronchioles and small bronchi. Loss of support as a 
consequence of airspace enlargement or selective loss of 
alveolar wall attachments may lead to distortion of small 
airways with obvious implications for airﬂ  ow limitation. 
As pointed out by Saetta et al (1985), all three alveolar 
attachment indices measured in this study can reﬂ  ect the 
destruction of alveolar attachments, but only the percent-
age abnormal attachments quantifies this destruction 
directly. In the total absence of an alveolar wall it would 
not be counted as abnormal, but such an instance would 
be reﬂ  ected in a reduction in the number of intact attach-
ments and a greater distance between intact attachments. 
All three treatment protocols (LPS:LPS, PPE:SAL, and 
PPE:LPS) signiﬁ  cantly increased percentage of abnormal 
attachments and the distance between normal attachments, 
and signiﬁ  cantly reduced the number of normal attach-
ments. The extent of change was generally more marked 
in the PPE:LPS segment.
The evidence presented suggests that chronic treat-
ment of sheep with LPS at the lung segmental level 
induces structural changes within the treated segment 
consistent with the deﬁ  nition of emphysema as deﬁ  ned at 
the National Heart, Lung and Blood Institute Workshop 
on the Deﬁ  nition of Emphysema in 1985 (Snider et al 
2003). Namely, “a condition of the lung characterized by 
abnormal, permanent enlargement of air spaces distal to 
the terminal bronchioles accompanied by destruction of 
their walls and without obvious ﬁ  brosis”. Further, although 
qualitative and quantitative similarities exist in relation to 
segmental treatment with elastase, there is a suggestion 
that chronic LPS treatment produces a more diffuse change 
throughout the lung segment, whereas elastase treatment 
is particularly focused around the airways.
A mild increase in absolute numbers of neutrophils was 
apparent in all segments at the culmination of the study in re-
lation to the baseline evaluation on day –7. In a study involv-
ing repeated bronchoalveolar lavage at 4- to 7-day intervals, 
we were unable to demonstrate any signiﬁ  cant changes in 
absolute BALF cell numbers over time (Collie et al 1999), 
implying that the observed increase is unlikely to be related 
to the procedural effect of repeated bronchoscopy. In sheep, 
treatment of lung segments with elastase induces an intense 
local neutrophilic inﬂ  ammatory response in the ﬁ  rst week, 
which changes in character to mononuclear in the second 
week and resolves over the course of the third week (Susskind 
et al 1985). Thus, changes in the PPE:SAL segments seen at 
day 39 are considered unlikely to be a direct consequence of 
the initial elastolytic insult. Intratracheal treatment of lambs 
with LPS causes an acute ﬁ  brinopurulent pneumonia, which 
resolves within 72 hours. Neutrophils are sequestered in 
the capillaries of the lungs and surfactant aggregates in the 
alveoli. Swelling of the alveolar and capillary endothelia, 
edema, hemorrhage, and emigration of neutrophils into the 
interstitium and small air spaces of the lungs occur subse-
quently (Cutlip et al 1998). Although it is likely that the inter-
val between treatments would be sufﬁ  cient for the major part 
of the above processes to resolve, it is unlikely that complete 
resolution would be realized, and it is therefore possible that 
the “lung-wide” changes are a consequence of the repeated 
inﬂ  ammatory insult in just two lung segments. The speciﬁ  c 
changes are likely to involve modiﬁ  ed adhesion molecule International journal of COPD 2006:1(2)
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expression on pulmonary vascular endothelia (Strieter and 
Kunkel 1994). Further, changes in the neutrophil vascular 
pool cannot be discounted. The exact nature of such change 
is speculative but might involve a shift in the proportion of 
blood neutrophils that are either normal, primed, activated, or 
senescent with according changes in the proportion that are 
phagocytically, chemotactically, and oxidatively active.
Similarly a signiﬁ  cant reduction in the elastase inhibi-
tory capacity of BALF from all segments was observed at 
the culmination of the study relative to baseline evaluation 
on day –7. Notably, on the pooled data from all segments a 
signiﬁ  cant negative correlation was demonstrated between 
absolute numbers of neutrophils and elastase inhibitory 
capacity, perhaps implying that neutrophil inﬂ  ux is linked 
to a progressive impairment of the elastase inhibitory 
screen. The failure to demonstrate any change in free 
neutrophil elastase in any segment could be interpreted 
as representing evidence that neutrophil elastase speciﬁ  c 
inhibitors in the bronchoalveolar space have not been 
completely overwhelmed at the point of sampling. Further, 
the evident lack of association between neutrophils, free 
neutrophil elastase, or elastase inhibitory capacity and the 
emphysema phenotype poses a question as to the relevance 
of these variables in the pathogenesis of emphysema in 
this model. Naturally the caveat that measurements are 
taken a week after the preceding treatment and do not in 
any case necessarily reﬂ  ect the potential for interstitial 
proteolysis should caution against overinterpretation of 
this lack of association. Acute neutrophilic inﬂ  ux, with 
attendant release of neutrophil elastase, may still play a 
predominant role in the pathogenesis of emphysema in 
this model.
TGF-βs are multifunctional cytokines that are usually 
secreted in a biologically latent form called either small or 
large latent TGF-β. The major aspect of controlling the activ-
ity of these cytokines rests with the conversion of latent to 
active TGF-β through proteolytic cleavage or conformational 
alteration of the latent complex. The former is believed to 
be largely mediated through plasmin and the latter through 
the interaction of RGD-motifs on the latency associated 
peptide with the integrin αvβ6 expressed on epithelial cells. 
Although much less is known in relation to the mechanisms 
that conspire to downregulate TGF-β activation, it is clear that 
a reduction in plasmin synthesis through TGF-β-mediated 
induction of plasminogen activator inhibitors or a reduction in 
the expression of the integrin αvβ6 might serve this purpose. 
The evidence that levels of active TGF-β are signiﬁ  cantly less 
than pre-treatment levels in LPS:LPS segments implies that 
control mechanisms seek to regulate a basal level of activa-
tion in the bronchoalveolar milieu, but that a consequence 
of chronic LPS administration is a downward regulation of 
this level. Whether reduced activation of TGF-β is a cause 
or consequence of the emphysema phenotype in this model 
system remains to be determined. However, downregulated 
activity of this cytokine has been clearly linked to an emphy-
sema phenotype and an upregulation of the monocyte–mac-
rophage-expressed elastase, matrix metalloproteinase-12, in 
αvβ6 gene deleted mice (Morris et al 2003), illustrating that 
the potential for a causative role certainly exists.
The presence of increased numbers of alveolar macro-
phages and lymphocytes in all treated segments at day 14 
relative to the SAL:SAL segment are, in the context of the 
elastase-treated segments, in common with the observations 
of Susskind et al (1985), who commented that during the ﬁ  rst 
week following elastase instillation there was an acute inﬂ  am-
matory response, primarily polymorphonuclear leukocytes, in 
the enzyme-treated lung, which changed to mononuclear cell 
inﬁ  ltrate during the course of the second week, and essen-
tially disappeared by the third week. Although not a feature 
recognized in BALF collected at the culmination of the study, 
a mononuclear alveolitis was identiﬁ  ed at the histopathologic 
level in LPS-treated segments 7 days after the last treatment. 
Such an alveolitis is also a feature of lung pathology follow-
ing long-term LPS instillation in mice (Vernooy et al 2002) 
and is accompanied, in this model, by dense peribronchial 
and perivascular lymphocytic aggregates.
The reduced numbers of eosinophils and mast cells seen 
in these sheep should be viewed in the context of the low 
absolute numbers involved, ie, in only 5% of the BALF sam-
ples did the percentage of eosinophils or mast cells exceed 
1% of the total cell count. Thus caution should be extended 
in interpreting these data. Nevertheless, it is conceivable that 
the reduced numbers present in BALF may be a reﬂ  ection of 
increased degranulation of this cell type in tissue compart-
ments as a consequence of tissue repair processes in treated 
lung. Certainly, mast cells play a fundamental role in tissue 
remodeling processes including degradation of matrix pro-
teins, promotion of vascular and epithelial permeability, and 
recruitment of inﬂ  ammatory cells and eosinophils, though the 
production of matrix metalloproteinases may play a similar 
role (Davis et al 1984; Ohno et al 1997).
In conclusion, our results indicate that repeated ad-
ministration of LPS at the lung segmental level in sheep 
results in the development of mild mononuclear alveolitis International Journal of COPD 2006:1(2) 199
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and downregulated activation of TGF-β in BALF. Although 
these features appear to be associated with the development 
of emphysema in treated lung segments, the relative role of 
neutrophil and mononuclear cell inﬁ  ltrates in contributing to 
such tissue-remodeling processes remains to be determined 
in this model.
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